Blueprint Medicines' GAAP loss for 3 months of 2022 was $105.999 million, up 6.3% from $99.714 million in the prior year. Revenue increased 2.9 times to $62.731 million from $21.576 million a year earlier.

Blueprint Medicines' GAAP loss for 2021 was $644.085 million, compared to a profit of $313.882 million in the previous year. Revenue decreased 77.3% to $180.08 million from $793.735 million a year earlier.

Blueprint Medicines has completed its acquisition of Lengo Therapeutics. The company develops therapeutics targeting driver mutations in oncology. The deal is worth $250 million. Blueprint will also pay an additional $215 million if LNG-451, a drug that could potentially treat non-small cell lung cancer patients with exon insertion mutations, reaches certain...

Blueprint Medicines is acquiring Lengo Therapeutics for $250 million. The company is developing new small-molecule precision therapeutics targeting driver mutations in oncology. Blueprint Medicines will also pay an additional $215 million if the investigational drug LNG-451, which could potentially treat non-small cell lung cancer patients with exon insertio...